Inhibition of cell migration for the development of antimetastatic agents;A tumorok áttétképzését korlátozó hatóanyagok kutatása

Magyar Onkologia

Volumn 50, Issue 2, 2006, Pages 93-100

  Jeney, András ^a,b   Kenessey, István ^a,b   Timár, Ferenc ^a,b   Oláh, Júlia ^a,b   Pogány, Gábor ^a,b   Babó, István ^a,b   Harisi, Reveka ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b MTA SE EKSZ Molekuláris Patológiai Kutató Csoport ^*  (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTINEOPLASTIC AGENT; BORRELIDIN; CHROMONE DERIVATIVE; DEOXYURIDINE; DOXORUBICIN; ENZYME INHIBITOR; FATTY ALCOHOL; FLAVONOID; IMIDAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; PACLITAXEL; PYRIDINE DERIVATIVE; RAPAMYCIN; RIBAVIRIN;

ANIMAL; CELL MOTION; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METASTASIS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CHROMONES; DEOXYURIDINE; DOXORUBICIN; ENZYME INHIBITORS; FATTY ALCOHOLS; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MORPHOLINES; NEOPLASM METASTASIS; PACLITAXEL; PYRIDINES; RIBAVIRIN; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 33750137054     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434-3437, 2001
2. Babó I, Bocsi J, Jeney A. The site-dependent growth characteristics of a human xenotransplanted basaloid squamous cell carcinoma. J Cancer Res Clin Oncol 125:35-41, 1999
3. Babó I, Zalatnai A, Schaff Z, et al. The pathomorphology of a human xenotransplanted basaloid squamous cell carcinoma. Neoplasma 45:210-215, 1998
4. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 60:1091-1099, 2000
5. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572, 2002
6. Cooper CR, Pienta KJ. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: A minireview. Prostate Cancer Prostatic Dis 3:6-12, 2000
7. Demeter A, Szirmai K, Oláh J, et al. A mátrix metalloproteázok aktivált formáinak megjelenése és a fibronektin koncentrációjának emelkedése recidiváló petefészekrákban. Orvosi Hetilap 145:1617-1624, 2004
8. Fidler IJ. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453-458, 2003
9. Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 3:362-374, 2003
10. Glinsky GV, Glinsky VV, Ivanova AB, et al. Apoptosis and metastasis: Increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 115:185-193, 1997
11. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8:128-135, 2002
12. Han S, Khuri FR, Roman J. Fibronectin stimulates nonsmall cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66:315-323, 2006
13. Harisi R, Dudás J, Pogány G, et al. Repopulation of osteosarcoma cells after treatment with doxorubicin in the presence of extracellular matrix biopolymers. Cancer Chemother Pharmacol 58:334-342, 2006
14. Harisi R, Dudás J, Timár F, et al. Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix. Anticancer Res 25:805-813, 2005
15. Harisi R, Dudás J, Timár F, et al. Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell culture. Cell Biol Int 29:959- 967, 2005
16. Hart IR, Saini A. Biology of tumour metastasis. Lancet 339:1453-1457, 1992
17. Hauptmann S, Budianto D, Denkert C, et al. Adhesion and migration of HRT-18 colorectal carcinoma cells on extracellular matrix components typical for the desmoplastic stroma of colorectal adenocarcinomas. Oncology 65:174-181, 2003
18. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91:22- 36, 1999
19. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100, 2002
20. Hutchinson JN, Jin J, Cardiff RD, et al. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res 64:3171-3178, 2004
21. Jeney A, Kopper L, Hidvégi E, et al. Pharmacobiochemical properties of 5-alkyl-2' deoxyuridine on tumor growth and glycoconjugate sxnthesis. Int J Exp Clin Chemother 4:32-39, 1991
22. Jeney A, Tímár J, Pogány G, et al. Glycosaminoglycans as novel target in antitumor therapy. Tokai J Exp Clin Med 15:167-177, 1990
23. Kellner B. A daganatos áttételek képzodé sére és azok chemotherápiás befolyá solására vonatkozó vizsgálatok. Orvosi Hetilap 98:1227-1230, 1957
24. Kopper L, Tímár J, Jeney A, et al. Glycosaminoglycan (GAG) metabolism as a potential target to prevent metastasis formation. Adv Exp Med Biol 233:367-375, 1988
25. Matrisian LM, Cunha GR, Mohla S. Epithelial-stromal interactions and tumor progression: Meeting summary and future directions. Cancer Res 61:3844-3846, 2001
26. Kentsis A, Topisirovic I, Culjkovic B, et al. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 101:18105-18110, 2004
27. Kim MS, Lee EJ, Kim HR, et al. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 63:5454-5461, 2003
28. Ladányi A, Nagy JO, Jeney A, et al. Cytokine sensitivity of metastatic human melanoma cell lines - simultaneous inhibition of proliferation and enhancement of gelatinase activity. Pathol Oncol Res 4:108-114, 1998
29. Lapis K, Nemeth L. Die wirkung des BCM auf die metastasenbildung transplantierter tiergeschwülste. Klin Wochenschr 34:864-867, 1956
30. Lapis K, Nemeth L. Effect of various chemotherapeutic agents on metastasis. Br J Cancer 10:719-723, 1956
31. Lapis K, Paku S, Liotta LA. Endothelialization of embolized tumor cells during metastasis formation. Clin Exp Metastasis 6:73-89, 1988
32. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584- 593, 2002
33. Nakajima K, Hirade K, Ishisaki A, et al. Akt regulates thrombin-induced HSP27 phosphorylation in aortic smooth muscle cells: Function at a point downstream from p38 MAP kinase. Life Sci 77:96-107, 2005
34. Ötvös L, Sági J, Sági G, et al. Enzymatic hydrolysis and biological activity of oligonucleotides containing 5- substituted pyrimidine bases. Nucleosides Nucleotides 18:1665-1666, 1999
35. Pogány G, Jeney A, Tímár J, et al. Modulation of glycoconjugate biosynthesis by 5-hexyl-2'-deoxyuridine in highly metastatic Lewis lung carcinoma cells. Neoplasma 37:501-510, 1990
36. Pogány G, Timár F, Oláh J, et al. Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. Oncology 60:274-281, 2001
37. Qian Y, Zhong X, Flynn DC, et al. ILK mediates actin filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene 24:3154-3165, 2005
38. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003
39. Ridley A. Molecular switches in metastasis. Nature 406:466-467, 2000
40. Sawada K, Morishige K, Tahara M, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 62:6015-6020, 2002
41. Shevde LA, Welch DR. Metastasis suppressor pathways - an evolving paradigm. Cancer Lett 198:1-20, 2003
42. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3:55-63, 2003
43. Swinnen JV, Beckers A, Brusselmans K, et al. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 65:2441-2448, 2005
44. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-54, 2002
45. Tímár J, Csuka O, Orosz Z, et al. Molecular pathology of tumor metastasis. I. Predictive pathology. Pathol Oncol Res 7:217-230, 2001
46. Tímár J, Csuka O, Orosz Z, et al. Molecular pathology of tumor metastasis. II. Molecular staging and differential diagnosis. Pathol Oncol Res 8:204-219, 2002
47. Tímár J, Diczházi C, Bartha I, et al. Modulation of heparan-sulphate/chondroitin-sulphate ratio by glycosaminoglycan biosynthesis inhibitors affects liver metastatic potential of tumor cells. Int J Cancer 62:755- 761, 1995
48. Tímár J, Jeney A, Kovalszky I, et al. Role of proteoglycans in tumor progression. Pathol Oncol Res 1:85-93, 1995
49. Tímár J, Moczar E, Timár F, et al. Comparative study on Lewis lung tumor lines with 'low' and 'high' metastatic capacity. II. Cytochemical and biochemical evidence for differences in glycosaminoglycans. Clin Exp Metastasis 5:79-87, 1987
50. Tímár J, Ladányi A, Peták I, et al. Molecular pathology of tumor metastasis III. Target array and combinatorial therapies. Pathol Oncol Res 9:49-72, 2003
51. Tímár J, Tóvári J, Pogány G, et al. The antimetabolite Tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells. Eur J Cancer 32A:152- 159, 1996
52. Toker A, Yoeli-Lerner M. Akt signaling and cancer: Surviving but not moving on. Cancer Res 66:3963-3966, 2006
53. Virtanen SS, Vaananen HK, Harkonen PL, et al. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62:2708-2714, 2002
54. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63:5679-5684, 2003